tyrosine and sirolimus

tyrosine has been researched along with sirolimus in 48 studies

Research

Studies (48)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	10 (20.83)	18.2507
2000's	25 (52.08)	29.6817
2010's	11 (22.92)	24.3611
2020's	2 (4.17)	2.80

Authors

Authors	Studies
Bierer, BE; Calvo, V; Crews, CM; Vik, TA	1
Giasson, E; Meloche, S	1
Bierer, BE; Calvo, V; Gjertson, C; Vik, T; Wood, M	1
Bergsma, DJ; Bossard, MJ; Cafferkey, R; Eng, WK; Faucette, L; Johnson, RK; Koser, PL; Levy, MA; Livi, GP; McLaughlin, MM; Sathe, GM	1
Frank, DA; Huo, L; Karras, JG; Rothstein, TL; Wang, Z; Zimmet, JM	1
Dennis, PB; Kozma, SC; Pullen, N; Thomas, G	1
Begum, N; Ragolia, L	1
DaSilva, L; Erwin, RA; Farrar, WL; Hennighausen, L; Kirken, RA; Liu, X; Malabarba, MG; Rui, H; Xu, J	1
Anand-Srivastava, MB; Pandey, SK; Srivastava, AK	1
DeFea, K; Li, J; Roth, RA	1
Sánchez-Margalet, V	1
Kramer, DL; Pederson, TM; Rondinone, CM	1
Chen, J; Freund, GG; Hartman, ME; Villela-Bach, M	1
Haruta, T; Iwata, M; Kawahara, J; Kobayashi, M; Takano, A; Uno, T; Usui, I	1
Barres, R; Gonzalez, T; Grémeaux, T; Gual, P; Le Marchand-Brustel, Y; Tanti, JF	1
Freund, GG; O'Connor, JC	1
Freund, GG; Godbout, JP; Hartman, ME; Mazzocco, VR; Minor, KD; O'Connor, JC	1
Ansani, L; Barbieri, D; Bettini, A; Campo, G; Cicchitelli, G; Ferrari, F; Ferrari, R; Guardigli, G; Malagutti, P; Parrinello, G; Percoco, G; Soukhomovskaia, O; Valgimigli, M	1
Boldyreff, B; Braun, S; Lösel, R; Wehling, M	1
Ansani, L; Barbieri, D; Bettini, A; Boersma, E; Campo, G; Cicchitelli, G; Ferrari, F; Ferrari, R; Guardigli, G; Malagutti, P; McFadden, EP; Merlini, F; Parrinello, G; Percoco, G; Valgimigli, M	1
Danielsson, A; Nystrom, FH; Ost, A; Strålfors, P	1
El Gaylani, N; Osman, F; Pitt, M; Qaisar, S	1
De Luca, L; Sardella, G	1
Aguiar, C; Almeida, M; de Araujo Goncalves, P; Ferreira, J; Pereira Machado, F; Raposo, L; Seabra-Gomes, R; Teles, R	1
Ligon, RW; Markwell, SJ; Mishkel, GJ; Moore, AL	1
Agostoni, P; Anselmi, M; Arcozzi, C; Bolognese, L; Campo, G; Cohen, DJ; Colangelo, S; de Cesare, N; Ferrari, R; Ferrario, M; Hamon, M; Malagutti, P; Parrinello, G; Pasquetto, G; Percoco, G; Prati, F; Rodriguez, AE; Sheiban, I; Valgimigli, M; Vassanelli, C; Vranckx, P	1
Arcozzi, C; Barbieri, D; Campo, G; Carletti, R; Ferrari, F; Ferrari, R; Malagutti, P; Parrinello, G; Percoco, G; Valgimigli, M	1
Arcozzi, C; Campo, G; Cohen, DJ; Dulisse, B; Ferrari, R; Isogai, PK; Mittmann, N; Percoco, G; Seung, SJ; Squasi, P; Valgimigli, M	1
Czernin, J; Hildebrandt, IJ; Phelps, ME; Su, H; Weber, WA; Wei, LH	1
Barja-Fidalgo, C; da Silva, SV; de Freitas, MS; Félix, GB; Garcia-Souza, EP; Moura, AS; Rodrigues, AL	1
Iavelov, IS	1
Gaestel, M; Niedenthal, R; Zimnik, S	1
Danzi, GB; Marzocchi, A	1
Ding, FH; DU, R; Hu, J; Shen, J; Shen, WF; Zhang, Q; Zhang, RY; Zhang, X; Zhao, LP	1
Akdemir, R; Cagirci, G; Karakurt, O; Kilic, H	1
Carvalheira, JB; Carvalho, HF; Clemente, CF; Dalla Costa, AP; Franchini, KG; Nadruz, W	1
Anselmi, M; Biondi-Zoccai, G; Boccuzzi, G; Bolognese, L; Campo, G; de Cesare, N; Díaz Fernández, JF; Ferrari, R; Malagutti, P; Moreno, R; Parrinello, G; Penzo, C; Ribichini, F; Rodriguez, AE; Russo, F; Valgimigli, M	1
Anselmi, M; Bolognese, L; Bressers, M; Bristot, L; Campo, G; Colangelo, S; De Cesare, N; Gambetti, S; Garcia-Garcia, HM; Garg, S; Monti, M; Moreno, R; Parrinello, G; Rodriguez, AE; Sarno, G; Serruys, PW; Valgimigli, M	1
Bolognese, L; Campo, G; Colangelo, S; de Cesare, N; Díaz Fernández, JF; Ferrari, R; Gambetti, S; Moreno, R; Nazzaro, MS; Parrinello, G; Penzo, C; Piva, T; Prati, F; Ribichini, F; Rodriguez, AE; Russo, F; Sheiban, I; Valgimigli, M; Vassanelli, C	1
Bolognese, L; Bramucci, E; Campo, G; Colangelo, S; Corrada, E; De Cesare, N; E Rodriguez, A; Ferrante, G; Ferrari, R; Moreno, R; Nazzaro, MS; Pasquetto, G; Piva, T; Prati, F; Presbitero, P; Sheiban, I; Valgimigli, M; Vassanelli, C	1
Chang, HW; Hwang, SL; Lee, JY; Li, X	1
Ergün, Y; Kılınç, M; Ozdemir, G; Sahin, E	1
Aiba, K; Isobe, K; Ito, S; Nishio, N; Oshino, R; Tanaka, Y; Thanasegaran, S	1
Chen, J; Hill, K; Lemasters, J; Sha, SH; Wang, X; Yang, SM; Yuan, H	1
Hua, H; Jiang, Y; Kong, Q; Li, M; Liu, S; Luo, T; Luo, Y; Shao, T; Wang, J; Wang, Q; Yin, Y	1
Cao, W; Feng, W; Gao, M; Huang, Z; Li, Q; Luo, H; Xiao, Q	1
Del Priore, G; Gartrell, BA; Retter, A; Roach, M; Scher, HI; Sokol, GH	1
Alain, T; Anton, L; Berman, AJ; Celucci, G; Chaker-Margot, M; Dajadian, C; Damgaard, CK; Fonseca, BD; Graber, TE; Hearnden, J; Hoang, HD; Hollensen, AK; Jia, JJ; Lahr, RM; Livingstone, M; Maier, T; Moraes, BJ; Niklaus, MR; Pena, IA; Pointet, R; Smith, EM; Solgaard, MT; Wang, XD; Yang, AD; Yu, Y	1

Reviews

2 review(s) available for tyrosine and sirolimus

Article	Year
[The MULTISTRATEGY study]. Giornale italiano di cardiologia (2006), 2009, Volume: 10, Issue:6 Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Drug Therapy, Combination; Drug-Eluting Stents; Electrocardiography; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Sirolimus; Stents; Tirofiban; Treatment Outcome; Tyrosine	2009
Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and S JACC. Cardiovascular interventions, 2011, Volume: 4, Issue:1 Topics: Abciximab; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cardiovascular Agents; Coronary Angiography; Coronary Circulation; Drug-Eluting Stents; Evidence-Based Medicine; Female; Humans; Immunoglobulin Fab Fragments; Kaplan-Meier Estimate; Male; Metals; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; No-Reflow Phenomenon; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sirolimus; Stents; Time Factors; Tirofiban; Treatment Outcome; Tyrosine	2011

Article

Year

[The MULTISTRATEGY study].

Giornale italiano di cardiologia (2006), 2009, Volume: 10, Issue:6

Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Drug Therapy, Combination; Drug-Eluting Stents; Electrocardiography; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Randomized Controlled Trials as Topic; Sirolimus; Stents; Tirofiban; Treatment Outcome; Tyrosine

2009

Persistent coronary no flow after wire insertion is an early and readily available mortality risk factor despite successful mechanical intervention in acute myocardial infarction: a pooled analysis from the STRATEGY (Single High-Dose Bolus Tirofiban and S

JACC. Cardiovascular interventions, 2011, Volume: 4, Issue:1

Topics: Abciximab; Aged; Analysis of Variance; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cardiovascular Agents; Coronary Angiography; Coronary Circulation; Drug-Eluting Stents; Evidence-Based Medicine; Female; Humans; Immunoglobulin Fab Fragments; Kaplan-Meier Estimate; Male; Metals; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; No-Reflow Phenomenon; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Randomized Controlled Trials as Topic; Risk Assessment; Risk Factors; Sirolimus; Stents; Time Factors; Tirofiban; Treatment Outcome; Tyrosine

2011

Trials

9 trial(s) available for tyrosine and sirolimus

Article	Year
High-dose bolus tirofiban and sirolimus eluting stent versus abiciximab and bare metal stent in acute myocardial infarction (STRATEGY) study--protocol design and demography of the first 100 patients. Cardiovascular drugs and therapy, 2004, Volume: 18, Issue:3 Topics: Abciximab; Antibodies, Monoclonal; Clinical Protocols; Coronary Restenosis; Drug Implants; Drug Therapy, Combination; Electrocardiography; Female; Forecasting; Humans; Immunoglobulin Fab Fragments; Injections; Italy; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation; Sirolimus; Stents; Time Factors; Tirofiban; Treatment Outcome; Tyrosine	2004
Tirofiban and sirolimus-eluting stent vs abciximab and bare-metal stent for acute myocardial infarction: a randomized trial. JAMA, 2005, May-04, Volume: 293, Issue:17 Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Drug Delivery Systems; Female; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Single-Blind Method; Sirolimus; Stents; Tirofiban; Tyrosine	2005
Two-by-two factorial comparison of high-bolus-dose tirofiban followed by standard infusion versus abciximab and sirolimus-eluting versus bare-metal stent implantation in patients with acute myocardial infarction: design and rationale for the MULTI-STRATEG American heart journal, 2007, Volume: 154, Issue:1 Topics: Abciximab; Antibodies, Monoclonal; Clinical Trials, Phase III as Topic; Drug Administration Schedule; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Infusions, Intravenous; Metals; Myocardial Infarction; Platelet Glycoprotein GPIIb-IIIa Complex; Randomized Controlled Trials as Topic; Research Design; Sirolimus; Stents; Tirofiban; Tyrosine	2007
Two-year clinical follow-up after sirolimus-eluting versus bare-metal stent implantation assisted by systematic glycoprotein IIb/IIIa Inhibitor Infusion in patients with myocardial infarction: results from the STRATEGY study. Journal of the American College of Cardiology, 2007, Jul-10, Volume: 50, Issue:2 Topics: Abciximab; Aged; Aged, 80 and over; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Combined Modality Therapy; Coronary Restenosis; Disease-Free Survival; Drug Delivery Systems; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Proportional Hazards Models; Prosthesis Design; Risk; Sirolimus; Stents; Tirofiban; Tyrosine	2007
A strategy to offset the extra cost of sirolimus-eluting stent in patients undergoing intervention for acute myocardial infarction. International journal of cardiology, 2008, Aug-01, Volume: 128, Issue:1 Topics: Abciximab; Aged; Antibodies, Monoclonal; Cost Control; Cost-Benefit Analysis; Drug-Eluting Stents; Female; Hospital Costs; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Infusions, Intravenous; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Prospective Studies; Sirolimus; Statistics, Nonparametric; Stents; Tirofiban; Treatment Outcome; Tyrosine	2008
[Tirofiban or abciximab and sirolimus-eluting or bare metal uncoated stents in primary percutaneous coronary intervention for acute myocardial infarction: results of MULTISTRATEGY trial]. Kardiologiia, 2008, Volume: 48, Issue:7 Topics: Abciximab; Antibodies, Monoclonal; Blood Vessel Prosthesis Implantation; Coated Materials, Biocompatible; Coronary Angiography; Electrocardiography; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Metals; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Retrospective Studies; Sirolimus; Stents; Tirofiban; Treatment Outcome; Tyrosine	2008
Three-year follow-up of the MULTIcentre evaluation of Single high-dose Bolus TiRofiban versus Abciximab with Sirolimus-eluting STEnt or Bare-Metal Stent in Acute Myocardial Infarction StudY (MULTISTRATEGY). International journal of cardiology, 2013, Apr-30, Volume: 165, Issue:1 Topics: Abciximab; Aged; Antibodies, Monoclonal; Drug Therapy, Combination; Drug-Eluting Stents; Female; Follow-Up Studies; Humans; Immunoglobulin Fab Fragments; Male; Metals; Middle Aged; Myocardial Infarction; Prospective Studies; Sirolimus; Stents; Tirofiban; Treatment Outcome; Tyrosine	2013
Sex-specific benefits of sirolimus-eluting stent on long-term outcomes in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: insights from the Multicenter Evaluation of Single High-Dose Bolus Tirofiban American heart journal, 2012, Volume: 163, Issue:1 Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Arrhythmias, Cardiac; Drug-Eluting Stents; Female; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Italy; Male; Middle Aged; Myocardial Infarction; Platelet Aggregation Inhibitors; Recurrence; Sex Factors; Sirolimus; Tirofiban; Tyrosine	2012
Phase II trial of SM-88, a cancer metabolism based therapy, in non-metastatic biochemical recurrent prostate cancer. Investigational new drugs, 2021, Volume: 39, Issue:2 Topics: Aged; Aged, 80 and over; Androgen Antagonists; Humans; Kaplan-Meier Estimate; Male; Methoxsalen; Middle Aged; Neoplasm Recurrence, Local; Phenytoin; Prostate-Specific Antigen; Prostatic Neoplasms; Quality of Life; Sirolimus; Tyrosine	2021

Other Studies

37 other study(ies) available for tyrosine and sirolimus

Article	Year
Interleukin 2 stimulation of p70 S6 kinase activity is inhibited by the immunosuppressant rapamycin. Proceedings of the National Academy of Sciences of the United States of America, 1992, Aug-15, Volume: 89, Issue:16 Topics: Animals; Calcium-Calmodulin-Dependent Protein Kinases; Cell Line; Chromatography, Ion Exchange; Immunoblotting; Immunosuppressive Agents; Interleukin-2; Kinetics; Mice; Molecular Weight; Phosphoproteins; Phosphotyrosine; Polyenes; Protein Kinase Inhibitors; Protein Kinases; Recombinant Proteins; Ribosomal Protein S6 Kinases; Sirolimus; Tacrolimus; Tetradecanoylphorbol Acetate; Tyrosine	1992
Role of p70 S6 protein kinase in angiotensin II-induced protein synthesis in vascular smooth muscle cells. The Journal of biological chemistry, 1995, Mar-10, Volume: 270, Issue:10 Topics: Angiotensin II; Angiotensin Receptor Antagonists; Animals; Aorta, Abdominal; Biphenyl Compounds; Cell Division; Cells, Cultured; DNA; Dose-Response Relationship, Drug; Electrophoresis, Polyacrylamide Gel; Enzyme Activation; Imidazoles; Kinetics; Losartan; Male; Molecular Weight; Muscle, Smooth, Vascular; Phosphoproteins; Phosphorylation; Phosphoserine; Phosphothreonine; Phosphotyrosine; Polyenes; Protein Biosynthesis; Protein Serine-Threonine Kinases; Pyridines; Rats; Rats, Inbred BN; Receptors, Angiotensin; Ribosomal Protein S6 Kinases; Sirolimus; Tetrazoles; Tyrosine	1995
Activation of 70-kDa S6 kinase, induced by the cytokines interleukin-3 and erythropoietin and inhibited by rapamycin, is not an absolute requirement for cell proliferation. European journal of immunology, 1994, Volume: 24, Issue:11 Topics: Animals; Carrier Proteins; Cell Cycle; Cell Division; Cells, Cultured; Enzyme Activation; Erythropoietin; Heat-Shock Proteins; Interleukin-3; Mice; Phosphorylation; Polyenes; Protein Serine-Threonine Kinases; Ribosomal Protein S6 Kinases; Sirolimus; Tacrolimus Binding Proteins; Tyrosine	1994
The tyrosine89 residue of yeast FKBP12 is required for rapamycin binding. Gene, 1993, 07-30, Volume: 129, Issue:2 Topics: Antifungal Agents; Base Sequence; Carrier Proteins; DNA Mutational Analysis; DNA, Fungal; Fungal Proteins; Immunosuppressive Agents; Molecular Probe Techniques; Molecular Sequence Data; Mutation; Polyenes; Protein Binding; Receptors, Drug; RNA-Binding Proteins; Saccharomyces cerevisiae; Saccharomyces cerevisiae Proteins; Sirolimus; Structure-Activity Relationship; Tacrolimus Binding Proteins; Tyrosine	1993
Delayed tyrosine phosphorylation and nuclear expression of STAT1 following antigen receptor stimulation of B lymphocytes. Journal of immunology (Baltimore, Md. : 1950), 1996, Sep-15, Volume: 157, Issue:6 Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; 3T3 Cells; Animals; Antibodies, Anti-Idiotypic; B-Lymphocytes; Cell Nucleus; DNA-Binding Proteins; Down-Regulation; Interferon Regulatory Factor-1; Lymphocyte Activation; Mice; Mice, Inbred BALB C; Nucleoproteins; Phosphoproteins; Phosphorylation; Polyenes; Protein Biosynthesis; Protein Serine-Threonine Kinases; Receptors, Antigen, B-Cell; Sirolimus; STAT1 Transcription Factor; Trans-Activators; Transcription Factors; Tyrosine	1996
The principal rapamycin-sensitive p70(s6k) phosphorylation sites, T-229 and T-389, are differentially regulated by rapamycin-insensitive kinase kinases. Molecular and cellular biology, 1996, Volume: 16, Issue:11 Topics: Amino Acid Sequence; Androstadienes; Cell Line; Humans; Immunosuppressive Agents; Kidney; Mitogen-Activated Protein Kinase Kinases; Molecular Sequence Data; Mutagenesis, Site-Directed; Nicotinic Acids; Peptide Mapping; Phosphates; Phosphodiesterase Inhibitors; Phosphopeptides; Phosphorylation; Polyenes; Protein Kinases; Protein Serine-Threonine Kinases; Recombinant Proteins; Ribosomal Protein S6 Kinases; Sequence Deletion; Sirolimus; Transfection; Tyrosine; Wortmannin	1996
cAMP counter-regulates insulin-mediated protein phosphatase-2A inactivation in rat skeletal muscle cells. The Journal of biological chemistry, 1996, Dec-06, Volume: 271, Issue:49 Topics: Androstadienes; Animals; Cells, Cultured; Cyclic AMP; Enzyme Inhibitors; Immunosuppressive Agents; Insulin; Kinetics; Muscle, Skeletal; Phosphoprotein Phosphatases; Phosphorylation; Polyenes; Protein Phosphatase 2; Rats; Sirolimus; Tyrosine; Vanadates; Wortmannin	1996
Two discrete regions of interleukin-2 (IL2) receptor beta independently mediate IL2 activation of a PD98059/rapamycin/wortmannin-insensitive Stat5a/b serine kinase. The Journal of biological chemistry, 1997, Jun-13, Volume: 272, Issue:24 Topics: Androstadienes; Animals; Cells, Cultured; DNA-Binding Proteins; Enzyme Activation; Enzyme Inhibitors; Flavonoids; Humans; Interleukin-2; Kinetics; Phosphorylation; Polyenes; Protein Serine-Threonine Kinases; Rats; Receptors, Interleukin-2; Serine; Sirolimus; Tumor Cells, Cultured; Tyrosine; Wortmannin	1997
Vanadyl sulfate-stimulated glycogen synthesis is associated with activation of phosphatidylinositol 3-kinase and is independent of insulin receptor tyrosine phosphorylation. Biochemistry, 1998, May-12, Volume: 37, Issue:19 Topics: Androstadienes; Animals; Calcium-Calmodulin-Dependent Protein Kinases; CHO Cells; Chromones; Cricetinae; Enzyme Activation; Flavonoids; Glycogen; Humans; Insulin Receptor Substrate Proteins; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Polyenes; Receptor, Insulin; Ribosomal Protein S6 Kinases; Sirolimus; Tyrosine; Vanadium Compounds; Wortmannin	1998
Modulation of insulin receptor substrate-1 tyrosine phosphorylation by an Akt/phosphatidylinositol 3-kinase pathway. The Journal of biological chemistry, 1999, Apr-02, Volume: 274, Issue:14 Topics: 3T3 Cells; Adipocytes; Animals; Endothelin-1; Flavonoids; Insulin; Insulin Receptor Substrate Proteins; Mice; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Platelet-Derived Growth Factor; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Sirolimus; Tyrosine	1999
Stimulation of glycogen synthesis by insulin requires S6 kinase and phosphatidylinositol-3-kinase in HTC-IR cells. Journal of cellular physiology, 2000, Volume: 182, Issue:2 Topics: Animals; Chromones; Enzyme Inhibitors; Flavonoids; Glycogen; Glycogen Synthase; Humans; Immunophilins; Insulin; Insulin Receptor Substrate Proteins; Isoenzymes; Mitogen-Activated Protein Kinases; Morpholines; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Rats; Ribosomal Protein S6 Kinases; Sirolimus; Tacrolimus Binding Proteins; Tumor Cells, Cultured; Tyrosine	2000
Serine/threonine phosphorylation of IRS-1 triggers its degradation: possible regulation by tyrosine phosphorylation. Diabetes, 2001, Volume: 50, Issue:1 Topics: 3T3 Cells; Androstadienes; Animals; Cysteine Endopeptidases; Enzyme Inhibitors; Insulin; Insulin Receptor Substrate Proteins; Mice; Multienzyme Complexes; Okadaic Acid; Phosphoproteins; Phosphorylation; Proteasome Endopeptidase Complex; Protein Kinase Inhibitors; Serine; Sirolimus; Threonine; Time Factors; Tyrosine; Vanadates; Wortmannin	2001
Frap-dependent serine phosphorylation of IRS-1 inhibits IRS-1 tyrosine phosphorylation. Biochemical and biophysical research communications, 2001, Jan-26, Volume: 280, Issue:3 Topics: Amino Acid Sequence; Animals; Carrier Proteins; Cell Line; Humans; Immunophilins; Insulin Receptor Substrate Proteins; Interferon-alpha; Janus Kinase 1; Phosphoproteins; Phosphorylation; Phosphotransferases (Alcohol Group Acceptor); Protein-Tyrosine Kinases; Rats; Ribosomal Protein S6 Kinases; Serine; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tyrosine	2001
Mammalian target of rapamycin pathway regulates insulin signaling via subcellular redistribution of insulin receptor substrate 1 and integrates nutritional signals and metabolic signals of insulin. Molecular and cellular biology, 2001, Volume: 21, Issue:15 Topics: Acetylcysteine; Adaptor Proteins, Signal Transducing; Adenoviridae; Amino Acids; Animals; Biological Transport; Carrier Proteins; Cell Cycle Proteins; Cell Line; Cysteine Endopeptidases; Cytosol; Deoxyglucose; Down-Regulation; Enzyme Inhibitors; Eukaryotic Initiation Factors; Glucose; Humans; Immunoblotting; Insulin; Insulin Receptor Substrate Proteins; Mice; Multienzyme Complexes; Phosphoproteins; Phosphorylation; Precipitin Tests; Proteasome Endopeptidase Complex; Protein Binding; Protein Kinases; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins; Proto-Oncogene Proteins c-akt; Ribosomal Protein S6 Kinases; Serine; Signal Transduction; Sirolimus; Subcellular Fractions; Threonine; Time Factors; TOR Serine-Threonine Kinases; Tyrosine	2001
Hyperosmotic stress inhibits insulin receptor substrate-1 function by distinct mechanisms in 3T3-L1 adipocytes. The Journal of biological chemistry, 2003, Jul-18, Volume: 278, Issue:29 Topics: 3T3 Cells; Adipocytes; Animals; Cell Membrane; Enzyme Activation; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Intracellular Signaling Peptides and Proteins; Mice; Osmotic Pressure; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Protein Kinase Inhibitors; Protein Kinases; Receptor, Insulin; Serine; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tyrosine	2003
Vanadate and rapamycin synergistically enhance insulin-stimulated glucose uptake. Metabolism: clinical and experimental, 2003, Volume: 52, Issue:6 Topics: Animals; Cell Line; Cysteine Endopeptidases; Cysteine Proteinase Inhibitors; Drug Synergism; Glucose; Hypoglycemic Agents; Insulin; Insulin Receptor Substrate Proteins; Leupeptins; Multienzyme Complexes; Phosphatidylinositol 3-Kinases; Phosphoinositide-3 Kinase Inhibitors; Phosphoproteins; Phosphorylation; Proteasome Endopeptidase Complex; Sirolimus; Tyrosine; Vanadates	2003
Insulin receptor substrate-2-dependent interleukin-4 signaling in macrophages is impaired in two models of type 2 diabetes mellitus. The Journal of biological chemistry, 2004, Jul-02, Volume: 279, Issue:27 Topics: Amino Acid Motifs; Animals; Blood Glucose; Blotting, Western; Cell Line; Diabetes Mellitus, Type 2; Glucose; Heterozygote; Humans; Insulin; Insulin Receptor Substrate Proteins; Interleukin-4; Intracellular Signaling Peptides and Proteins; Macrophages; Macrophages, Peritoneal; Mice; Mice, Inbred C57BL; Mice, Transgenic; Phosphatidylinositol 3-Kinases; Phosphoproteins; Phosphorylation; Serine; Signal Transduction; Sirolimus; Tetradecanoylphorbol Acetate; Time Factors; Tyrosine; U937 Cells	2004
Aldosterone rapidly activates Src kinase in M-1 cells involving the mineralocorticoid receptor and HSP84. FEBS letters, 2004, Jul-16, Volume: 570, Issue:1-3 Topics: Aldosterone; Animals; Blotting, Western; Cell Line; Dose-Response Relationship, Drug; Enzyme Activation; Heat-Shock Proteins; HSP90 Heat-Shock Proteins; Kidney; Mice; Phosphorylation; Precipitin Tests; Receptors, Mineralocorticoid; Sirolimus; Spironolactone; src-Family Kinases; Time Factors; Tyrosine	2004
Attenuation of insulin-stimulated insulin receptor substrate-1 serine 307 phosphorylation in insulin resistance of type 2 diabetes. The Journal of biological chemistry, 2005, Oct-14, Volume: 280, Issue:41 Topics: Adipocytes; Aged; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Electrophoresis, Gel, Two-Dimensional; Electrophoresis, Polyacrylamide Gel; Female; Humans; Immunoblotting; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Kinetics; Male; Middle Aged; Okadaic Acid; Phosphoproteins; Phosphorylation; Serine; Signal Transduction; Sirolimus; Time Factors; Tyrosine	2005
Tirofiban plus sirolimus-eluting stent vs abciximab plus bare-metal stent. JAMA, 2005, Oct-05, Volume: 294, Issue:13 Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Drug Delivery Systems; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Sirolimus; Stents; Tirofiban; Tyrosine	2005
Tirofiban plus sirolimus-eluting stent vs abciximab plus bare-metal stent. JAMA, 2005, Oct-05, Volume: 294, Issue:13 Topics: Abciximab; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Drug Delivery Systems; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Myocardial Infarction; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Sirolimus; Stents; Thrombectomy; Tirofiban; Tyrosine	2005
Complementary effects of sirolimus-eluting stents and glycoprotein IIb/IIIa inhibitors for percutaneous coronary intervention in diabetic patients: one-year follow up of a single-centre registry. Heart (British Cardiac Society), 2006, Volume: 92, Issue:8 Topics: Coronary Restenosis; Diabetic Angiopathies; Disease-Free Survival; Drug Combinations; Drug Implants; Eptifibatide; Follow-Up Studies; Humans; Immunosuppressive Agents; Peptides; Platelet Aggregation Inhibitors; Platelet Glycoprotein GPIIb-IIIa Complex; Sirolimus; Stents; Tirofiban; Tyrosine	2006
Bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitors in drug-eluting stent implantations in the absence of acute myocardial infarction: clinical and economic results. The Journal of invasive cardiology, 2007, Volume: 19, Issue:2 Topics: Abciximab; Aged; Antibodies, Monoclonal; Anticoagulants; Coronary Artery Disease; Costs and Cost Analysis; Drug Delivery Systems; Drug Therapy, Combination; Eptifibatide; Female; Heparin; Hirudins; Humans; Immunoglobulin Fab Fragments; Immunosuppressive Agents; Length of Stay; Male; Middle Aged; Myocardial Infarction; Paclitaxel; Peptide Fragments; Peptides; Platelet Glycoprotein GPIIb-IIIa Complex; Recombinant Proteins; Retrospective Studies; Sirolimus; Stents; Tirofiban; Treatment Outcome; Tyrosine	2007
Changes in tumor metabolism as readout for Mammalian target of rapamycin kinase inhibition by rapamycin in glioblastoma. Clinical cancer research : an official journal of the American Association for Cancer Research, 2008, Jun-01, Volume: 14, Issue:11 Topics: Animals; Antibiotics, Antineoplastic; Cell Line, Tumor; Cell Proliferation; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Glioblastoma; Glucose; Humans; Mice; Positron-Emission Tomography; Protein Kinases; Sirolimus; Thymidine; Thymidine Kinase; TOR Serine-Threonine Kinases; Tyrosine	2008
Maternal protein restriction during early lactation induces GLUT4 translocation and mTOR/Akt activation in adipocytes of adult rats. American journal of physiology. Endocrinology and metabolism, 2008, Volume: 295, Issue:3 Topics: Adipocytes; Adipose Tissue; Animals; Antibiotics, Antineoplastic; Blotting, Western; Bridged Bicyclo Compounds, Heterocyclic; Cell Separation; Chromones; Diet, Protein-Restricted; Enzyme Inhibitors; Female; Glucose; Glucose Transporter Type 4; Hypoglycemic Agents; Immunohistochemistry; Insulin; Lactation; Morpholines; Oncogene Protein v-akt; Phosphorylation; Protein Kinases; Protein Transport; Rats; Rats, Wistar; Sirolimus; Thiazolidines; TOR Serine-Threonine Kinases; Tyrosine	2008
Mutually exclusive STAT1 modifications identified by Ubc9/substrate dimerization-dependent SUMOylation. Nucleic acids research, 2009, Volume: 37, Issue:4 Topics: Cell Line; Dimerization; Humans; Protein Processing, Post-Translational; Sirolimus; Small Ubiquitin-Related Modifier Proteins; STAT1 Transcription Factor; Tyrosine; Ubiquitin-Conjugating Enzymes	2009
Triple antiplatelet therapy for clopidogrel resistance with stent malapposition: a case report. Chinese medical journal, 2009, Sep-20, Volume: 122, Issue:18 Topics: Angioplasty, Balloon, Coronary; Aspirin; Clopidogrel; Coronary Angiography; Drug-Eluting Stents; Humans; Male; Middle Aged; Platelet Aggregation; Platelet Aggregation Inhibitors; Sirolimus; Ticlopidine; Tirofiban; Treatment Outcome; Tyrosine	2009
Resolution of late sirolimus-eluting stent thrombosis after tirofiban treatment. Heart and vessels, 2009, Volume: 24, Issue:5 Topics: Adult; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Coronary Angiography; Coronary Circulation; Coronary Thrombosis; Drug-Eluting Stents; Electrocardiography; Fibrinolytic Agents; Humans; Infusions, Intra-Arterial; Male; Sirolimus; Thrombolytic Therapy; Tirofiban; Treatment Outcome; Tyrosine	2009
FAK mediates the activation of cardiac fibroblasts induced by mechanical stress through regulation of the mTOR complex. Cardiovascular research, 2010, Jun-01, Volume: 86, Issue:3 Topics: Actins; Animals; Animals, Newborn; Apoptosis; Cell Differentiation; Cell Proliferation; Cells, Cultured; Collagen Type I; Enzyme Activation; Fibroblasts; Focal Adhesion Kinase 1; Intracellular Signaling Peptides and Proteins; Leucine; Matrix Metalloproteinase 2; Mechanotransduction, Cellular; Myocardium; Oligopeptides; Phosphorylation; Protein Serine-Threonine Kinases; Proto-Oncogene Proteins c-akt; Rats; Rats, Wistar; Ribosomal Protein S6 Kinases; RNA Interference; Serine; Sirolimus; Stress, Mechanical; Threonine; Time Factors; TOR Serine-Threonine Kinases; Tuberous Sclerosis Complex 2 Protein; Tumor Suppressor Proteins; Tyrosine	2010
Prediction of 1-year clinical outcomes using the SYNTAX score in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention: a substudy of the STRATEGY (Single High-Dose Bolus Tirofiban and Sirolim JACC. Cardiovascular interventions, 2011, Volume: 4, Issue:1 Topics: Abciximab; Aged; Angioplasty, Balloon, Coronary; Antibodies, Monoclonal; Cardiovascular Agents; Coronary Angiography; Disease-Free Survival; Drug-Eluting Stents; Female; Humans; Immunoglobulin Fab Fragments; Kaplan-Meier Estimate; Male; Metals; Middle Aged; Multicenter Studies as Topic; Myocardial Infarction; Platelet Aggregation Inhibitors; Predictive Value of Tests; Proportional Hazards Models; Randomized Controlled Trials as Topic; Recurrence; Retrospective Studies; Risk Assessment; Risk Factors; ROC Curve; Severity of Illness Index; Sirolimus; Stents; Thrombosis; Time Factors; Tirofiban; Treatment Outcome; Tyrosine	2011
Improved insulin sensitivity by rapamycin is associated with reduction of mTOR and S6K1 activities in L6 myotubes. Biochemical and biophysical research communications, 2012, Feb-10, Volume: 418, Issue:2 Topics: Animals; Cell Line; Endoplasmic Reticulum Stress; Gene Knockdown Techniques; Glucose; Insulin; Insulin Receptor Substrate Proteins; Insulin Resistance; Muscle Fibers, Skeletal; Phosphorylation; Rats; Ribosomal Protein S6 Kinases; Sirolimus; TOR Serine-Threonine Kinases; Tyrosine	2012
Rapamycin inhibits oxidative and angiogenic mediators in diabetic retinopathy. Canadian journal of ophthalmology. Journal canadien d'ophtalmologie, 2014, Volume: 49, Issue:5 Topics: Angiogenesis Modulating Agents; Animals; Anti-Bacterial Agents; Diabetes Mellitus, Experimental; Diabetic Retinopathy; Eye Proteins; Hypoxia-Inducible Factor 1, alpha Subunit; Male; Malondialdehyde; Nerve Growth Factors; Oxidative Stress; Rats; Rats, Wistar; Serpins; Sirolimus; Tyrosine; Vascular Endothelial Growth Factor A	2014
GADD34 inhibits activation-induced apoptosis of macrophages through enhancement of autophagy. Scientific reports, 2015, Feb-09, Volume: 5 Topics: Animals; Apoptosis; Autophagy; Caspase 3; Cell Line; Cysteine; Gene Expression; Gene Knockdown Techniques; Humans; Lipopolysaccharides; Macrophage Activation; Macrophages; Mice; Mice, Knockout; Protein Phosphatase 1; Signal Transduction; Sirolimus; TOR Serine-Threonine Kinases; Tyrosine	2015
Autophagy attenuates noise-induced hearing loss by reducing oxidative stress. Antioxidants & redox signaling, 2015, May-20, Volume: 22, Issue:15 Topics: Acetylcysteine; Aldehydes; Animals; Antioxidants; Autophagy; Hair Cells, Auditory, Outer; Hearing Loss, Noise-Induced; Male; Mice; Microtubule-Associated Proteins; Oxidative Stress; Sirolimus; Tyrosine	2015
mTORC2 promotes type I insulin-like growth factor receptor and insulin receptor activation through the tyrosine kinase activity of mTOR. Cell research, 2016, Volume: 26, Issue:1 Topics: Carrier Proteins; Cell Line, Tumor; Cell Proliferation; HEK293 Cells; Hep G2 Cells; Humans; Mechanistic Target of Rapamycin Complex 2; Multiprotein Complexes; Phosphorylation; Protein-Tyrosine Kinases; Rapamycin-Insensitive Companion of mTOR Protein; Receptor, IGF Type 1; Receptor, Insulin; Sirolimus; TOR Serine-Threonine Kinases; Tyrosine	2016
Blockade of Y177 and Nuclear Translocation of Bcr-Abl Inhibits Proliferation and Promotes Apoptosis in Chronic Myeloid Leukemia Cells. International journal of molecular sciences, 2017, Mar-02, Volume: 18, Issue:3 Topics: Apoptosis; Cell Line, Tumor; Cell Nucleus; Cell Proliferation; Drug Resistance, Neoplasm; Fusion Proteins, bcr-abl; Humans; Leukemia, Myelogenous, Chronic, BCR-ABL Positive; MAP Kinase Signaling System; Nuclear Localization Signals; Protein Transport; Sirolimus; STAT5 Transcription Factor; Tyrosine	2017
mTORC1 promotes TOP mRNA translation through site-specific phosphorylation of LARP1. Nucleic acids research, 2021, 04-06, Volume: 49, Issue:6 Topics: Amino Acid Motifs; Autoantigens; HEK293 Cells; Humans; Mechanistic Target of Rapamycin Complex 1; Naphthyridines; Phosphorylation; Protein Binding; Protein Biosynthesis; Ribonucleoproteins; Serine; Sirolimus; SS-B Antigen; Threonine; Tyrosine	2021